Six priorities to advance the science and practice of coral reef restoration worldwide

Coral reef restoration is a rapidly growing movement galvanized by the accelerating degradation of the world's tropical coral reefs. The need for concerted and collaborative action focused on the recovery of coral reef ecosystems coalesced in the creation of the Coral Restoration Consortium (CRC) in 2017. In March 2020, the CRC leadership team met for a biennial review of international coral reef restoration efforts and a discussion of perceived knowledge and implementation bottlenecks that may impair scalability and efficacy. Herein we present six priorities wherein the CRC will foster scientific advancement and collaboration to: (1) increase restoration efficiency, focusing on scale and cost-effectiveness of deployment; (2) scale up larval-based coral restoration efforts, emphasizing recruit health, growth, and survival; (3) ensure restoration of threatened coral species proceeds within a population-genetics management context; (4) support a holistic approach to coral reef ecosystem restoration; (5) develop and promote the use of standardized terms and metrics for coral reef restoration; and (6) support coral reef restoration practitioners working in diverse geographic locations. These priorities are not exhaustive nor do we imply that accomplishing these tasks alone will be sufficient to restore coral reefs globally; rather these are topics where we feel the CRC community of practice can make timely and significant contributions to facilitate the growth of coral reef restoration as a practical conservation strategy. The goal for these collective actions is to provide tangible, local-scale advancements in reef condition that offset declines resulting from local and global stressors including climate change

A Family of Helminth Molecules that Modulate Innate Cell Responses via Molecular Mimicry of Host Antimicrobial Peptides

Over the last decade a significant number of studies have highlighted the central role of host antimicrobial (or defence) peptides in modulating the response of innate immune cells to pathogen-associated ligands. In humans, the most widely studied antimicrobial peptide is LL-37, a 37-residue peptide containing an amphipathic helix that is released via proteolytic cleavage of the precursor protein CAP18. Owing to its ability to protect against lethal endotoxaemia and clinically-relevant bacterial infections, LL-37 and its derivatives are seen as attractive candidates for anti-sepsis therapies. We have identified a novel family of molecules secreted by parasitic helminths (helminth defence molecules; HDMs) that exhibit similar biochemical and functional characteristics to human defence peptides, particularly CAP18. The HDM secreted by Fasciola hepatica (FhHDM-1) adopts a predominantly α-helical structure in solution. Processing of FhHDM-1 by F. hepatica cathepsin L1 releases a 34-residue C-terminal fragment containing a conserved amphipathic helix. This is analogous to the proteolytic processing of CAP18 to release LL-37, which modulates innate cell activation by classical toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS). We show that full-length recombinant FhHDM-1 and a peptide analogue of the amphipathic C-terminus bind directly to LPS in a concentration-dependent manner, reducing its interaction with both LPS-binding protein (LBP) and the surface of macrophages. Furthermore, FhHDM-1 and the amphipathic C-terminal peptide protect mice against LPS-induced inflammation by significantly reducing the release of inflammatory mediators from macrophages. We propose that HDMs, by mimicking the function of host defence peptides, represent a novel family of innate cell modulators with therapeutic potential in anti-sepsis treatments and prevention of inflammation

Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature

Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor which has been used in conjunction with other anti-cancer agents in the treatment of patients with many cancers. It remains controversial whether bevacizumab can prolong survival in cancer patients. This meta-analysis was therefore performed to evaluate effect of bevacizumab on survival in cancer patients. PubMed, EMBASE, and Web of Science databases were searched for English-language studies of randomized controlled trials comparing bevacizumab with control therapy published through February 8, 2012. Progression-free survival, overall survival, and one-year survival rate were analyzed using random- or fixed-effects model. Thirty one assessable randomized controlled trials were identified. A significant improvement in progression-free survival in cancer patients was attributable to bevacizumab compared with control therapy (hazard ratio, 0.72; 95% confidence interval, 0.68 to 0.76; p<0.001). Overall survival was also significantly longer in patients were treated with bevacizumab (hazard ratio, 0.87; 95% confidence interval, 0.83 to 0.91; p<0.001). The significant benefit in one-year survival rate was further seen in cancer patients receiving bevacizumab (odds ratio, 1.30; 95% confidence interval, 1.20 to 1.41; p<0.001). Current evidences showed that bevacizumab prolong progression-free survival and overall survival, and increase one-year survival rate in cancer patients as compared with control therapy

Multi-decadal satellite measurements of global volcanic degassing

© 2016 The Authors. Satellite instruments have been providing measurements of global volcanic emissions of sulfur dioxide (SO2) since 1978, based on observations in the ultraviolet (UV), infrared (IR) and microwave spectral bands. We review recent advances in satellite remote sensing of volcanic gases, focusing on increased instrument sensitivity to tropospheric SO2 emissions and techniques to determine volcanic plume altitude. A synthesis of ~36 years of global UV, IR and microwave satellite measurements yields an updated assessment of the volcanic SO2 flux to the upper troposphere and lower stratosphere (UTLS) between 1978 and 2014 (~1-Tg/yr). The present availability of multiple UV and IR satellite SO2 products provides increased confidence in calculated SO2 loadings for many eruptions. We examine the temporal and latitudinal distribution of volcanic SO2 emissions and reassess the relationship between eruptive SO2 discharge and eruption magnitude, finding a first-order correlation between SO2 emission and volcanic explosivity index (VEI), but with significant scatter. Based on the observed SO2-VEI relation, we estimate the fraction of eruptive SO2 emissions released by the smallest eruptions (~0.48 Tg/yr), which is not recorded by satellite observations. A detailed breakdown of the sources of measured SO2 emissions reveals intuitively expected correlations between eruption frequency, SO2 loading and volcanic degassing style. We discuss new constraints on e-folding times for SO2 removal in volcanic plumes, and highlight recent measurements of volcanic hydrogen chloride (HCl) injections into the UTLS. An analysis of passive volcanic emissions of SO2 detected in Ozone Monitoring Instrument (OMI) SO2 data since 2004 provides new insight into the location and stability of the dominant sources of volcanic SO2 over the past decade. Since volcanic SO2 emissions constitute a random, highly variable perturbation to the atmosphere-climate system, continued monitoring of volcanic SO2 emissions from space by multiple UV and IR instruments to extend the current multi-decadal record is essential, and near-global, geostationary measurements of SO2 may be available by the end of the current decade